- Arbutus Biopharma (ABUS, Financial) to present five abstracts at EASL Congress 2025 in Amsterdam.
- Key findings include the efficacy of Imdusiran and AB-101 in treating chronic hepatitis B.
- Presentations scheduled for May 7-10, 2025, focusing on significant advancements in HBV treatments.
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company, has announced the acceptance of five abstracts for presentation at the European Association for the Study of the Liver (EASL) Congress 2025, scheduled to take place from May 7 to 10, 2025, in Amsterdam. The abstracts will cover vital developments on their two leading drug candidates, Imdusiran and AB-101, which are aimed at addressing chronic hepatitis B (HBV). These presentations are a significant milestone for Arbutus as they highlight breakthrough findings in their ongoing research and clinical trials.
The IM-PROVE I study of Imdusiran highlighted key factors influencing functional cures in chronic hepatitis B patients. The research showed that baseline HBsAg levels and NA discontinuation were crucial. Particularly, subjects attained rapid HBV RNA decline during treatment, with 5 out of 6 achieving undetectable levels. Notably, transient HBV RNA elevations during interferon therapy correlated with further HBsAg decrease.
On the other hand, AB-101, an oral PD-L1 inhibitor, demonstrated promising results in its early trials. These trials confirmed the safety and tolerability of AB-101 across single and multiple doses. Significant findings include dose-responsive increases in PD-L1 receptor occupancy and high liver biodistribution, with meaningful receptor occupancy at doses as low as 10 mg. These promising results reflect AB-101's potential in treating chronic hepatitis B by re-activating exhausted HBV-specific T-cells.
Arbutus plans to continue advancing its research and clinical programs to offer potential treatments for chronic HBV, a condition affecting over 250 million individuals globally. The presentations at the EASL Congress 2025 signal a significant step in addressing the unmet medical needs of HBV patients through innovative therapeutic solutions by Arbutus Biopharma.
